David H. Kirn

21.8k citations

144 papers · 15.8k indexed · 4 hit papers · h-index 64

Genetics top 0.02%
Oncology top 0.1%
Molecular Biology top 0.5%
Biotechnology top 0.02%
Immunology top 1%

Co-authors: Carla Heise Frank McCormick Ta‐Chiang Liu Adam Sampson-Johannes Steve H. Thorne John C. Bell Caroline J. Breitbach Tae-Ho Hwang
Topics: Virus-based gene therapy research (119 papers)CAR-T cell therapy research (66 papers)Cancer Research and Treatments (50 papers)
Cited by: Genetics Biotechnology Oncology
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom Canada

In The Last Decade

David H. Kirn

143 papers receiving 15.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

1996 1.4k citations David H. Kirn, Carla Heise et al. profile →
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

2000 858 citations Carla Heise, David H. Kirn et al. Nature Medicine profile →
An essential role for Rac in Ras transformation

1995 792 citations Rongguo Qiu, David H. Kirn et al. profile →
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1997 745 citations Carla Heise, Adam Sampson-Johannes et al. Nature Medicine profile →

Peers

Countries citing papers authored by David H. Kirn

Since Specialization

Citations

This map shows the geographic impact of David H. Kirn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Kirn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Kirn more than expected).

Fields of papers citing papers by David H. Kirn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Kirn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Kirn. The network helps show where David H. Kirn may publish in the future.

Co-authorship network of co-authors of David H. Kirn

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Kirn. A scholar is included among the top collaborators of David H. Kirn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Kirn. David H. Kirn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies 2023 ·Journal of Clinical Investigation ·(unknown),Manuela Corti,Kirsten E. Coleman,(unknown),Julie Berthy,Precilla D’Souza,Cynthia J. Tifft,Roland W. Herzog,Melissa E. Elder,Lawrence R. Shoemaker,Carmen Leon‐Astudillo,(unknown),David H. Kirn,Jonathan D. Schwartz,Barry J. Byrne	67
2	WS05.01 AAV mediated gene therapy for cystic fibrosis: interim results from a phase 1/2 clinical trial 2023 ·Journal of Cystic Fibrosis ·Jennifer L. Taylor‐Cousar,Raksha Jain,(unknown),Terrence Sullivan,Robert Fishman,David H. Kirn,Daniel Dorgan	2
3	The natural history of choroideremia; progressive loss of visual function and retinal structure 2020 ·Investigative Ophthalmology & Visual Science ·David G. Birch,Paul S. Bernstein,Ian M. MacDonald,(unknown),David Liao,Kirsten G. Locke,(unknown),(unknown),(unknown),(unknown),Somayeh Honarmand,Paul Jordan,Ulrich F. O. Luhmann,David H. Kirn,Peter J. Francis	3
4	Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms 2017 ·Cancer Research ·Minah Kim,Maximilian Nitschké,Barbara Sennino,Patrizia Murer,Brian J. Schriver,(unknown),(unknown),(unknown),Jiahu Wang,(unknown),Marie‐Claude Bourgeois‐Daigneault,David H. Kirn,John C. Bell,Naomi De Silva,Caroline J. Breitbach,Donald M. McDonald	55
5	The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) 2015 ·PubMed ·Caroline J. Breitbach,John C. Bell,Tae-Ho Hwang,David H. Kirn,James M. Burke	46
6	Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer 2015 ·Molecular Therapy ·Se Hoon Park,Caroline J. Breitbach,Jeeyun Lee,Joon Oh Park,Ho Yeong Lim,Won Ki Kang,Anne Moon,(unknown),(unknown),(unknown),(unknown),Adina Pelusio,James M. Burke,(unknown),David H. Kirn,Young Suk Park	140
7	Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans 2013 ·Cancer Research ·Caroline J. Breitbach,Rozanne Arulanandam,Naomi De Silva,Steve H. Thorne,Richard H. Patt,Manijeh Daneshmand,Anne Moon,Carolina S. Ilkow,James M. Burke,Tae-Ho Hwang,Jeong Heo,Mong Cho,Hannah Chen,Fernando A. Angarita,Christina Addison,J. Andrea McCart,John C. Bell,David H. Kirn	208
8	Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells 2012 ·Cancer Research ·Lee‐Hwa Tai,Christiano Tanese de Souza,Simon Bélanger,Lundi Ly,Almohanad A. Alkayyal,Jiqing Zhang,Julia L. Rintoul,Abhirami A. Ananth,Tiffany Lam,Caroline J. Breitbach,Theresa Falls,David H. Kirn,John C. Bell,Andrew P. Makrigiannis,Rebecca C. Auer	187
9	Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594 2012 ·Current Pharmaceutical Biotechnology ·Caroline J. Breitbach,Steve H. Thorne,John C. Bell,David H. Kirn	35
10	A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma 2011 ·Molecular Therapy ·Tae-Ho Hwang,Anne Moon,James M. Burke,Antoni Ribas,Joe Stephenson,Caroline J. Breitbach,Manijeh Daneshmand,Naomi De Silva,Kelley A. Parato,Jean‐Simon Diallo,Yeon-Sook Lee,Ta‐Chiang Liu,John C. Bell,David H. Kirn	122
11	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers 2011 ·Molecular Therapy ·Kelley A. Parato,Caroline J. Breitbach,Fabrice Le Bœuf,Jiahu Wang,(unknown),Carolina S. Ilkow,Jean‐Simon Diallo,Theresa Falls,Joseph K. Burns,Vanessa da Silva Garcia,Femina Kanji,Laura Evgin,Kang Hu,Francois Paradis,Shane Knowles,Tae-Ho Hwang,Barbara C. Vanderhyden,Rebecca C. Auer,David H. Kirn,John C. Bell	224
12	The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma 2008 ·Molecular Therapy ·Ta‐Chiang Liu,Tae-Ho Hwang,(unknown),John C. Bell,David H. Kirn	161
13	A phase I-II clinical trial with JX-594, a targeted and GM-CSF-armed oncolytic poxvirus, by intratumoral injection in patients with liver tumors 2007 ·Molecular Cancer Therapeutics ·(unknown),Tae-Ho Hwang,(unknown),(unknown),(unknown),Hyuk-Chan Kwon,(unknown),(unknown),Kelly Speth,Anne Crompton,Patrick W. Trown,M. Jason Hatfield,Ta‐Chiang Liu,Herbert M. Pinedo,John C. Bell,David H. Kirn	5
14	Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development 2005 ·Molecular Therapy ·Terry Hermiston,David H. Kirn	8
15	Oncolytic Virotherapy as a Novel Treatment Platform for Cancer 2003 ·PubMed ·David H. Kirn	7
16	An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy 2000 ·Nature Medicine ·Carla Heise,Terry Hermiston,Leisa Johnson,Gabriel Brooks,Adam Sampson-Johannes,(unknown),(unknown),David H. Kirn	483
17	Rac1-Induced Endocytosis Is Associated with Intracellular Proteolysis during Migration through a Three-Dimensional Matrix 2000 ·Experimental Cell Research ·Mamoun Ahram,Mansoureh Sameni,Rongguo Qiu,Bruce E. Linebaugh,David H. Kirn,Bonnie F. Sloane	37
18	ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agentsbreakdown → 1997 ·Nature Medicine ·Carla Heise,Adam Sampson-Johannes,(unknown),Frank McCormick,Daniel D. Von Hoff,David H. Kirn	745
19	Section Review: Oncologic, Endocrine & Metabolic: New treatment approaches for metastatic breast cancer 1995 ·Expert Opinion on Investigational Drugs ·David H. Kirn	2
20	Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer 1993 ·Journal of Thoracic and Cardiovascular Surgery ·David H. Kirn,Thomas J. Lynch,Steven J. Mentzer,Thomas H. Lee,Gary M. Strauss,Anthony Elias,Arthur T. Skarin,David J. Sugarbaker	22

About David H. Kirn

David H. Kirn is a scholar working on Biotechnology, Genetics and Oncology, having authored 144 papers that have together received 15.8k indexed citations. Recurring topics across this work include Virus-based gene therapy research (119 papers), CAR-T cell therapy research (66 papers) and Cancer Research and Treatments (50 papers). The work is most often cited by research in Genetics (12.1k citations), Biotechnology (3.3k citations) and Oncology (8.9k citations). David H. Kirn has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Carla Heise, Frank McCormick, Ta‐Chiang Liu, Adam Sampson-Johannes, Steve H. Thorne, John C. Bell, Caroline J. Breitbach, Tae-Ho Hwang, Britta Randlev and Rongguo Qiu. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact